{
  "1": {
    "premise": "Outcome Measurement: Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab. Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL within 10 days after the first dose of denosumab. For all CSC values, if albumin was ≤ 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 × (4 - serum albumin [g/dL])). Time frame: 10 days. Results: Overall Number of Participants Analyzed: 33. Unit of Measure: percentage of participants: 63.6% (95% CI: 45.1 to 79.6).",
    "statement": "Denosumab corrects serum calcium levels in participants",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "2": {
    "premise": "Adverse Events 1: Total: 4/11 (36.36%). Blood bilirubin increased 1/11 (9.09%), Febrile neutropenia 1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia (Sinus tachycardia) 1/11 (9.09%), Sepsis 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09%).",
    "statement": "The treatment was effective, although carries associated risks to hematologic health, heart rhythm, and immune response.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "3": {
    "premise": "Outcome Measurement: Proportion of Patients With Blood Pressure <140/90 mmHg at Week 12. Blood pressure was measured at baseline and at week 12 after starting amlodipine. Time Frame: 12 weeks. Results: 70.2% of 47 patients had blood pressure <140/90 mmHg at week 12. 95% CI: 56.4 to 81.8.",
    "statement": "Amlodipine lowers blood pressure in patients.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "4": {
    "premise": "Outcome Measurement: Percentage of Patients With HbA1c <7% After 24 Weeks of Treatment With Sitagliptin. HbA1c levels were assessed at baseline and at the end of 24 weeks. Time Frame: 24 weeks. Results: 58.3% of 60 patients achieved HbA1c <7%. 95% CI: 44.9 to 70.9.",
    "statement": "Sitagliptin causes a reduction in HbA1c levels in patients.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "5": {
    "premise": "Adverse Events Summary: Total: 5/15 (33.33%). Elevated liver enzymes 2/15 (13.33%), Nausea 1/15 (6.67%), Thrombocytopenia 1/15 (6.67%), Bradycardia 1/15 (6.67%), Hypokalemia 1/15 (6.67%).",
    "statement": "The treatment proved effective, though some patients experienced issues with liver function, heart rate, and electrolyte balance.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "6": {
    "premise": "Adverse Events Summary: 6/20 (30.00%). Headache 3/20 (15.00%), Fatigue 2/20 (10.00%), Rash 1/20 (5.00%). All adverse events were Grade 1 or 2.",
    "statement": "The drug was effective and safe, but commonly caused mild side effects such as headache and fatigue.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "7": {
    "premise": "Treatment-Emergent Adverse Events: 7/18 (38.89%). Anemia 2/18 (11.11%), Hypertension 2/18 (11.11%), Dizziness 1/18 (5.56%), Insomnia 1/18 (5.56%), Constipation 1/18 (5.56%).",
    "statement": "While the treatment was beneficial, patients frequently experienced elevated blood pressure and sleep disturbances.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "8": {
    "premise": "Outcome: Proportion of patients achieving LDL cholesterol <100 mg/dL after 8 weeks of atorvastatin therapy. Results: 52.4% (11/21) of patients achieved the target. Time frame: 8 weeks.",
    "statement": "Atorvastatin effectively lowers LDL cholesterol in most patients.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "9": {
    "premise": "Outcome: Rate of wound healing at Day 14 following topical application of silver sulfadiazine. 40% (8/20) of wounds showed full epithelialization by Day 14. Time frame: 14 days.",
    "statement": "Silver sulfadiazine accelerates wound healing within two weeks.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "10": {
    "premise": "Outcome: Percentage of participants with pain reduction ≥30% on a 10-point scale at Week 6 following treatment with oral tramadol. 65% (13/20) met the pain reduction threshold. No control group included.",
    "statement": "Oral tramadol reduced pain levels significantly by Week 6.",
    "label": "neutral",
    "Reasoning type:": "causal"
  },
  "11": {
    "premise": "78-year-old patient with stage IV HER2-positive breast cancer receiving daily paclitaxel at 315 mg/m² for 12 weeks, along with standard trastuzumab therapy (initial loading dose of 4 mg/kg followed by 2 mg/kg weekly for 12 weeks, then 6 mg/kg every 3 weeks for 40 weeks).",
    "statement": "The patient is expected to experience clinical benefit from their treatment regimen, leading to disease stabilization and improved overall prognosis.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "12": {
    "premise": "65-year-old male with non-Hodgkin lymphoma receiving cyclophosphamide at 415mg/m² intravenously on Days 1–5 of each 21-day cycle, for 4 cycles.",
    "statement": "The treatment is expected to result in some reduction in lymph node size, with durable response and extended survival.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "13": {
    "premise": "68-year-old female with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min/1.73m²) receiving metformin 1000mg twice daily.",
    "statement": "The treatment is expected to improve glycemic control, reduce cardiovascular risk, and provide long-term kidney protection.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "14": {
    "premise": "45‑year‑old patient with squamous cell carcinoma receiving weekly cetuximab at 250mg/m² and cisplatin at 250mg/m² daily for 7 days.",
    "statement": "The patient is expected to show partial regression of the tumor, with a favorable clinical response and improved progression-free survival.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "15": {
    "premise": "72-year-old patient with advanced non-small cell lung cancer receiving cisplatin at 120mg/m² on Day 1 and vinorelbine 30mg/m² on Days 1 and 8 of a 21-day cycle, repeated for 6 cycles.",
    "statement": "The patient is expected to experience tumor response with improved respiratory function and overall clinical benefit.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "16": {
    "premise": "53-year-old female with triple-negative breast cancer receiving doxorubicin 90mg/m² every week for 8 weeks.",
    "statement": "The patient is expected to respond well to the regimen, with meaningful tumor shrinkage and sustained clinical benefit.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "17": {
    "premise": "2-month-old infant diagnosed with metastatic melanoma receiving pembrolizumab 200mg intravenously every 3 weeks.",
    "statement": "The therapy is expected to induce an immune response against the tumor and improve the clinical outlook.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "18": {
    "premise": "59-year-old male with relapsed acute lymphoblastic leukemia receiving methotrexate 250mg/m² intravenously daily for 10 consecutive days.",
    "statement": "The treatment is expected to reduce leukemic burden and improve survival prospects.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "19": {
    "premise": "64-year-old patient with advanced pancreatic cancer receiving gemcitabine 1250mg/m² intravenously on Days 1–5 every 21 days for four cycles.",
    "statement": "The treatment is expected to relieve symptoms and prolong overall survival.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "20": {
    "premise": "60-year-old male with head and neck squamous cell carcinoma receiving cisplatin 250mg/m² daily for 7 consecutive days along with standard radiation therapy.",
    "statement": "The regimen is expected to enhance tumor control and improve survival outcomes.",
    "label": "contradiction",
    "Reasoning type:": "comp"
  },
  "21": {
    "premise": "67-year-old male presented with mild lower urinary tract symptoms, including frequency and a weak urinary stream. Digital rectal examination was unremarkable. Blood tests revealed a PSA level of 9.2 ng/mL. The case was reviewed by Consultant Urologist Dr. M. Rahman, who made a diagnosis of prostate cancer based on the PSA result. The patient was informed of the diagnosis and referred to oncology for further management. No imaging or biopsy was arranged at this stage.",
    "statement": "The patient has prostate cancer",
    "label": "contradiction",
    "Reasoning type:": "epsitemic"
  },
  "22": {
    "premise": "A 34-year-old male presents to the emergency department with sudden onset chest pain radiating to his left arm, shortness of breath, and diaphoresis. ECG shows ST-elevation in leads II, III, and aVF. Troponin is markedly elevated. The attending physician rules out myocardial infarction and concludes that the patient is experiencing heartburn due to spicy food eaten earlier. The patient is discharged with antacids and advised to avoid chili.",
    "statement": "The patient is experiencing heartburn.",
    "label": "contradiction",
    "Reasoning type:": "epsitemic"
  },
  "23": {
    "premise": "A 66-year-old man with no significant past medical history presents with severe, tearing chest pain radiating to the back. Blood pressure is markedly different between arms. The emergency physician diagnoses musculoskeletal pain and prescribes NSAIDs.",
    "statement": "The patient has an aortic dissection.",
    "label": "entailment",
    "Reasoning type:": "epsitemic"
  },
  "24": {
    "premise": "A 25-year-old female comes in with fever, flank pain, and dysuria. Urine culture is positive for E. coli. Despite this, the physician suggests that the pain is likely due to a pulled muscle and no antibiotics are prescribed.",
    "statement": "The patient has a urinary tract infection.",
    "label": "entailment",
    "Reasoning type:": "epsitemic"
  },
  "25": {
    "premise": "A 59-year-old woman presents with a persistent cough, weight loss, and night sweats. Chest X-ray shows a large mass in the right upper lobe. The clinician diagnoses her with pneumonia and prescribes antibiotics without further workup.",
    "statement": "The patient has lung cancer.",
    "label": "entailment",
    "Reasoning type:": "epsitemic"
  },
  "26": {
    "premise": "A 38-year-old woman presents with episodes of palpitations, anxiety, and sweating. Her blood pressure is 180/110 mm Hg. No labs or imaging are done. The physician diagnoses panic disorder and refers her to a therapist.",
    "statement": "The patient has panic disorder.",
    "label": "contradiction",
    "Reasoning type:": "epsitemic"
  },
  "27": {
    "premise": "The patient reported that her persistent cough and weight loss were due to seasonal allergies. However, further workup revealed a mass in the left lung and a biopsy confirmed adenocarcinoma.",
    "statement": "The patient has seasonal allergies.",
    "label": "contradiction",
    "Reasoning type:": "epsitemic"
  },
  "28": {
    "premise": "A 60-year-old male underwent knee replacement surgery on June 5, 2023. At his postoperative follow-up on May 30, 2023, he reported no complications and good mobility.",
    "statement": "The patient followed up after his knee replacement surgery.",
    "label": "contradiction",
    "Reasoning type:": "epsitemic"
  },
  "29": {
    "premise": "A 50-year-old man presents with worsening fatigue, hypotension, and hyperpigmentation of the skin. Laboratory results reveal low cortisol and elevated ACTH levels. The physician diagnoses the patient with depression and prescribes SSRIs.",
    "statement": "The patient has Addison's disease.",
    "label": "entailment",
    "Reasoning type:": "epsitemic"
  },
  "30": {
    "premise": "A 22-year-old woman arrives at the emergency department after fainting during exercise. ECG reveals a prolonged QT interval. Her symptoms are attributed to dehydration, and she is discharged with fluids and electrolyte tablets.",
    "statement": "The patient has long QT syndrome.",
    "label": "entailment",
    "Reasoning type:": "epsitemic"
  },
  "31": {
    "statement": "The patient requires urgent outpatient evaluation.",
    "premise": "Patient (52M), currently on holiday, presents with several months' history of nasal congestion (blocked, crusty), generalized fatigue, and widespread myalgia. Reports feeling generally unwell.",
    "label": "entailment",
    "Reasoning type:": "risk"
  },
  "32": {
    "statement": "Pneumonia is ruled out for this patient",
    "premise": "A 40-year-old female presents with a mild fever and pain localized to the renal angle. She denies any coughing and her pulse is within normal limits. Based on her symptoms, she suspects she may have pyelonephritis.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "33": {
    "statement": "Given the patient’s stable condition, the consultant’s decision to delay the lumbar puncture until the following day is safe.",
    "premise": "Patient presents with clinical features suggestive of meningitis. Currently hemodynamically stable, afebrile, and alert. No signs of raised intracranial pressure on examination. Lumbar puncture was attempted but unsuccessful. Discussed with Consultant Dr. A. Smith, who reviewed the case and, given the patient’s stability and presumed viral etiology, advised deferring the procedure. Empirical antiviral therapy was initiated. No antibiotics started at this stage. Plan for lumbar puncture to be performed by senior consultant on 06/07/2025.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "34": {
    "premise": "A 45-year-old man with a known shellfish allergy experienced an episode of anaphylaxis after dining at a restaurant. Shortly after eating, he developed breathing difficulty and collapsed. He was administered intramuscular epinephrine at the scene but lost consciousness. Witnesses reported tonic-clonic movements and urinary incontinence during the episode. He was taken to the emergency department, where he received intravenous adrenaline and supportive care.",
    "statement": "The patient should be referred to the First Seizure (FIT) clinic.",
    "label": "entailment",
    "Reasoning type:": "risk"
  },
  "35": {
    "premise": "Adverse Events: A 72-year-old patient receiving chemotherapy developed febrile neutropenia on Day 10 of Cycle 1. Temperature was 38.6°C, absolute neutrophil count (ANC) 0.2 x10⁹/L. Managed as outpatient with oral antibiotics. No hospital admission or IV antibiotics were arranged. Patient monitored via phone follow-up.",
    "statement": "The adverse event was managed appropriately.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "36": {
    "premise": [
      "Adverse Events 1:",
      "  Total: 35/51 (68.63%)",
      "  Constipation 20/51 (39.22%)",
      "  Blood disorder 1/51 (1.96%)",
      "  Hypomagnesemia 1/51 (1.96%)",
      "  Platelets count decrease 1/51 (1.96%)",
      "  Thrombosis 6/51 (11.7%)",
      "  Vision-blurred vision 1/51 (1.96%)",
      "  Radiation oesophagitis 1/51 (1.96%)",
      "  Nausea 2/51 (3.92%)",
      "  Vomiting 2/51 (3.92%)",
      "  General symptom 2/51 (3.92%)",
      "  Headache 1/51 (1.96%)",
      "  Bone pain 1/51 (1.96%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of constipation.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "37": {
    "premise": [
      "Adverse Events 2:",
      "  Total: 40/60 (66.67%)",
      "  Fatigue 25/60 (41.67%)",
      "  Anaphylaxis 3/60 (5.00%)",
      "  Injection site reaction 4/60 (6.67%)",
      "  Rash 2/60 (3.33%)",
      "  Headache 3/60 (5.00%)",
      "  Dizziness 2/60 (3.33%)",
      "  Mild hypotension 1/60 (1.67%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of fatigue.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "38": {
    "premise": [
      "Adverse Events 3:",
      "  Total: 28/55 (50.91%)",
      "  Dry mouth 18/55 (32.73%)",
      "  Bradycardia 2/55 (3.64%)",
      "  Syncope 1/55 (1.82%)",
      "  Transient dizziness 3/55 (5.45%)",
      "  Injection site reaction 2/55 (3.64%)",
      "  Anxiety 1/55 (1.82%)",
      "  Fatigue 1/55 (1.82%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of dry mouth.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "39": {
    "premise": [
      "Adverse Events 7:",
      "  Total: 50/70 (71.43%)",
      "  Injection site pain 20/70 (28.57%)",
      "  Myocardial infarction 3/70 (4.29%)",
      "  Hypertensive crisis 5/70 (7.14%)",
      "  Seizure 2/70 (2.86%)",
      "  Dizziness 3/70 (4.29%)",
      "  Nausea 2/70 (2.86%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of injection site pain.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  },
  "40": {
    "premise": [
      "Adverse Events 8:",
      "  Total: 55/80 (68.75%)",
      "  Fatigue 25/80 (31.25%)",
      "  Anaphylaxis 3/80 (3.75%)",
      "  Respiratory distress 5/80 (6.25%)",
      "  Hypotension 4/80 (5.00%)",
      "  Diarrhea 4/80 (5.00%)",
      "  Rash 3/80 (3.75%)"
    ],
    "statement": "The highest patient risk was associated with the occurrence of fatigue.",
    "label": "contradiction",
    "Reasoning type:": "risk"
  }
}